Literature DB >> 20660274

Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.

Loréline Jouve1, Pascal Salin, Christophe Melon, Lydia Kerkerian-Le Goff.   

Abstract

The thalamic centromedian-parafascicular (CM/Pf) complex, mainly represented by Pf in rodents, is proposed as an interesting target for the neurosurgical treatment of movement disorders, including Parkinson's disease. In this study, we examined the functional impact of subchronic high-frequency stimulation (HFS) of Pf in the 6-hydroxydopamine-lesioned hemiparkinsonian rat model. Pf-HFS had significant anti-akinetic action, evidenced by alleviation of limb use asymmetry (cylinder test). Whereas this anti-akinetic action was moderate, Pf-HFS totally reversed lateralized neglect (corridor task), suggesting potent action on sensorimotor integration. At the cellular level, Pf-HFS partially reversed the dopamine denervation-induced increase in striatal preproenkephalin A mRNA levels, a marker of the neurons of the indirect pathway, without interfering with the markers of the direct pathway (preprotachykinin and preprodynorphin). Pf-HFS totally reversed the lesion-induced changes in the gene expression of cytochrome oxidase subunit I in the subthalamic nucleus, the globus pallidus, and the substantia nigra pars reticulata, and partially in the entopeduncular nucleus. Unlike HFS of the subthalamic nucleus, Pf-HFS did not induce per se dyskinesias and directly, although partially, alleviated L-3,4-dihydroxyphenylalanine (L-DOPA)-induced forelimb dyskinesia. Conversely, L-DOPA treatment negatively interfered with the anti-parkinsonian effect of Pf-HFS. Altogether, these data show that Pf-DBS, by recruiting a large basal ganglia circuitry, provides moderate to strong anti-parkinsonian benefits that might, however, be affected by L-DOPA. The widespread behavioral and cellular outcomes of Pf-HFS evidenced here demonstrate that CM/Pf is an important node for modulating the pathophysiological functioning of basal ganglia and related disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660274      PMCID: PMC6632817          DOI: 10.1523/JNEUROSCI.1404-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  21 in total

1.  Gamma band activity in the developing parafascicular nucleus.

Authors:  Nebojsa Kezunovic; James Hyde; Christen Simon; Francisco J Urbano; D Keith Williams; Edgar Garcia-Rill
Journal:  J Neurophysiol       Date:  2011-11-16       Impact factor: 2.714

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Activation of the thalamic parafascicular nucleus by electrical stimulation of the peripheral vestibular nerve in rats.

Authors:  Nari Kim; Myoung Ae Choi; Ho Koo; Byung Rim Park; Sang Who Han; Chaejoon Cheong; Min Sun Kim
Journal:  Exp Brain Res       Date:  2017-03-06       Impact factor: 1.972

Review 4.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

5.  Targeting thalamic circuits rescues motor and mood deficits in PD mice.

Authors:  Ying Zhang; Dheeraj S Roy; Yi Zhu; Yefei Chen; Tomomi Aida; Yuanyuan Hou; Chenjie Shen; Nicholas E Lea; Margaret E Schroeder; Keith M Skaggs; Heather A Sullivan; Kyle B Fischer; Edward M Callaway; Ian R Wickersham; Ji Dai; Xiao-Ming Li; Zhonghua Lu; Guoping Feng
Journal:  Nature       Date:  2022-06-08       Impact factor: 69.504

6.  Visualization of fast calcium oscillations in the parafascicular nucleus.

Authors:  James Hyde; Nebojsa Kezunovic; Francisco J Urbano; Edgar Garcia-Rill
Journal:  Pflugers Arch       Date:  2013-04-16       Impact factor: 3.657

7.  Pathway-Specific Remodeling of Thalamostriatal Synapses in Parkinsonian Mice.

Authors:  Philip R L Parker; Arnaud L Lalive; Anatol C Kreitzer
Journal:  Neuron       Date:  2016-01-28       Impact factor: 17.173

8.  Primary culture of mouse dopaminergic neurons.

Authors:  Florence Gaven; Philippe Marin; Sylvie Claeysen
Journal:  J Vis Exp       Date:  2014-09-08       Impact factor: 1.355

9.  Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson's disease induced by unilateral stereotaxic injection of 6-ohda in rat.

Authors:  Dayane Pessoa de Araújo; Caren Nádia Soares De Sousa; Paulo Victor Pontes Araújo; Carlos Eduardo de Souza Menezes; Francisca Taciana Sousa Rodrigues; Sarah Souza Escudeiro; Nicole Brito Cortez Lima; Manoel Claúdio Azevedo Patrocínio; Lissiana Magna Vasconcelos Aguiar; Glauce Socorro de Barros Viana; Silvânia Maria Mendes Vasconcelos
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

10.  Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.

Authors:  Rodolphe Hajj; Aude Milet; Damien Toulorge; Nathalie Cholet; Julien Laffaire; Julie Foucquier; Sandra Robelet; Richard Mitry; Mickael Guedj; Serguei Nabirotchkin; Ilya Chumakov; Daniel Cohen
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.